X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/01/24/2815094/0/en/SparingVision-Reaches-Final-Dose-Escalation-Step-in-PRODYGY-Trial-with-SPVN06-for-retinitis-pigmentosa.html
https://www.globenewswire.com//news-release/2023/08/30/2734166/0/en/SparingVision-Reports-Positive-Initial-Safety-Data-from-the-first-cohort-treated-in-its-PRODYGY-Phase-I-II-Gene-Therapy-Trial.html
https://www.globenewswire.com/news-release/2023/07/12/2703375/0/en/SparingVision-sells-ex-vivo-GIRK-technology-to-Tenpoint-Therapeutics.html
https://www.globenewswire.com/news-release/2023/04/05/2641518/0/en/SparingVision-appoints-Joseph-C-Papa-as-Chairman.html
https://www.globenewswire.com//news-release/2022/12/01/2565749/0/en/SparingVision-s-lead-asset-SPVN06-clears-IND-application-in-the-US-for-the-treatment-of-retinitis-pigmentosa.html
https://www.globenewswire.com/news-release/2022/12/01/2565749/0/en/SparingVision-s-lead-asset-SPVN06-clears-IND-application-in-the-US-for-the-treatment-of-retinitis-pigmentosa.html
https://www.globenewswire.com/news-release/2022/09/14/2515575/0/en/SparingVision-Raises-75-Million-Series-B-to-Continue-Building-World-Leading-Portfolio-of-Genomic-Medicines-for-Ocular-Diseases.html
https://www.fiercebiotech.com/biotech/after-a-gene-editing-first-intellia-grabs-10-stake-sparingvision-for-collab-eye-gene
https://www.globenewswire.com/news-release/2021/04/20/2213110/0/en/SparingVision-Expands-Novel-Ocular-Disease-Pipeline-with-Acquisition-of-GAMUT-Therapeutics.html
https://www.globenewswire.com/news-release/2020/10/21/2111528/0/en/SparingVision-Raises-44-5-Million-and-Appoints-St%C3%A9phane-Boissel-as-Chief-Executive-Officer.html#:~:text=SparingVision%20Raises%20%E2%82%AC44.5%20Million%20and%20Appoints%20St%C3%A9phane%20Boissel%20as%20Chief%20Executive%20Officer,-Email%20Print%20Friendly&text=Paris%2C%20October%2021%2C%202020%20%E2%80%93,%E2%82%AC44.5%20million%20financing%20round.
Market Place
Share 
